Compare ASTE & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTE | MPLT |
|---|---|---|
| Founded | 1972 | 2018 |
| Country | United States | United States |
| Employees | N/A | 133 |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2003 | N/A |
| Metric | ASTE | MPLT |
|---|---|---|
| Price | $53.03 | $29.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $66.00 | $32.67 |
| AVG Volume (30 Days) | 163.9K | ★ 255.6K |
| Earning Date | 05-06-2026 | 05-28-2026 |
| Dividend Yield | ★ 0.85% | N/A |
| EPS Growth | ★ 784.21 | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.72 | N/A |
| Revenue Next Year | $5.44 | N/A |
| P/E Ratio | $876.17 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $37.83 | $12.24 |
| 52 Week High | $65.69 | $33.28 |
| Indicator | ASTE | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 53.33 | 52.75 |
| Support Level | $50.25 | $26.07 |
| Resistance Level | $54.17 | $31.69 |
| Average True Range (ATR) | 2.04 | 2.47 |
| MACD | 0.50 | -0.14 |
| Stochastic Oscillator | 76.31 | 68.33 |
Astec Industries Inc designs and manufactures equipment and components used in road construction and other development activities. Its products are used through the entire process of building roads, from mining and crushing materials to creating the road surface. The company manufactures a line of plants, pavers, vehicles, and machines to mix and transform materials into construction components. The company has two operating segments: infrastructure solutions generating maximum revenue and materials solutions. The majority of sales are derived from the United States. Its customers are asphalt producers, highway and heavy equipment contractors, ready mix concrete producers, demolition recycling markets, sand and gravel producers, open mine operators, quarry operators, and others.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.